Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab + relatlimab fixed-dose combination versus nivolumab after complete resection of stage III-IV melanoma
2021-001641-13Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Nivolumab + relatlimab fixed-dose combination with Nivolumab monotherapy (2 arms). Primary endpoint: Recurrence-free survival. Started Jul 2021; status: active.
02
Drugs
nivolumabrelatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2021-001641-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001641-13.